SPEED survey measures dry eye symptoms

Article

The Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire is a repeatable and valid method to measure dry eye symptoms, reveals a recent paper in the journal Cornea.

The Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire is a repeatable and valid method to measure dry eye symptoms, reveals a recent paper in the journal Cornea.

Dr William Ngo et al., Centre for Contact Lens Research, University of Waterloo, Waterloo, Ontario, Canada, conducted a study on 50 subjects, with 30 as identified as symptomatic and 20 asymptomatic. The SPEED questionnaire was used on all patients, as well as the McMonnies dry eye survey, the Ocular Surface Disease Index (OSDI), dry eye questionnaire and subjective evaluation of symptoms.

All questionnaires were completed in a random order two visits, with clinical measurements obtained on the first visit. Concordance correlation coefficient was used to determine repeatability, whereas Rasch analyses, principal component and factor was used to determine dimensionality. SPEED scores were compared with dry eye diagnosis based on OSDI to measure validity.

SPEED survey data was undimensional and repeatable, with the three principal symptoms of dry eye identified. This included dryness, burning and soreness/fatigue. The only clinical measures that strongly correlated with SPEED questionnaire scores were corneal staining, meibomian gland score and meibomian glands yielding liquid secretion score.

To read the abstract please click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.